Completed PHASE3 INTERVENTIONAL 2-arm NCT00840671

Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke (CERE-LYSE-1)

A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

Sponsor: Ever Neuro Pharma GmbH

Conditions Stroke

Interventions 0.9% Saline Solution Cerebrolysin

Updated 6 times since 2017 Last updated: Dec 27, 2010 Started: Oct 31, 2005 Primary completion: Mar 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00840671, this PHASE3 trial focuses on Stroke and remains completed. Sponsored by Ever Neuro Pharma GmbH, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ever Neuro Pharma GmbH
JSW-Research Forschungslabor GmbH, Parkring 12, 8074 Grambach

Data source: Ever Neuro Pharma GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bratislava, Slovakia , Brno, Czechia , Gugging, Austria , Innsbruck, Austria , Klagenfurt, Austria , Linz, Austria , Ljubljana, Slovenia , Ostrava, Czechia , Ostrava Vitkovice, Czechia , Pilsen, Czechia and 4 more locations